Dark

Check out our Dark Pool Levels

BMBIF
BRIGHT MINDS BIOSCIENCES INC COM (Canada)
stock OTC

No price data

0.00USD0.000%(0.00)0

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewExchangesShortsNews

Jan 4, 2022

04:05PM EST Bright Minds Biosciences to Present at the H.C. Wainwright GlobeNewswire Inc

Dec 6, 2021

06:50AM EST Bright Minds Biosciences (Bright Minds, BMB or the Company) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference as follows: GlobeNewswire Inc

Nov 30, 2021

07:30AM EST Hundreds of de novo patentable psychedelic-based compounds created through discovery program GlobeNewswire Inc

Nov 3, 2021

06:50AM EDT Bright Minds Biosciences Commences Trading on the Nasdaq Under the GlobeNewswire Inc

Oct 18, 2021

01:37PM EDT Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation Benzinga

08:36AM EDT KCSA Psychedelics Virtual Investor Conference Presentations Available for PR Newswire

Oct 13, 2021

04:25PM EDT There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are Benzinga

Oct 7, 2021

08:35AM EDT Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com PR Newswire

Oct 6, 2021

06:50AM EDT Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright Minds, will present at the LD Micro Main Event Small Cap Investment Conference as follows: GlobeNewswire Inc

Sep 8, 2021

06:50AM EDT Bright Minds Biosciences to Present at the Virtual H.C. Wainwright GlobeNewswire Inc

Sep 7, 2021

04:15PM EDT CORRECTION: Bumble Ticker Is 'BMBL' Benzinga

04:13PM EDT Bumble Inc. Announces Offering Of 15M Shares Of Common Stock By Selling Shareholders Benzinga

Aug 18, 2021

07:00AM EDT -- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- GlobeNewswire Inc

Jul 26, 2021

10:56AM EDT Bright Minds' Second-Gen Psychedelic Drugs Ready to Be Embraced by Investors, Big Pharma Benzinga

Jun 16, 2021

06:50AM EDT Bright Minds Biosciences Announces Application to List on Nasdaq GlobeNewswire Inc

Jun 14, 2021

04:05PM EDT Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced a new appointment to its Board of Directors and one addition to its leadership team: GlobeNewswire Inc

Jun 11, 2021

08:00AM EDT Bright Minds Biosciences to Present at the H.C. Wainwright Virtual GlobeNewswire Inc

Jun 9, 2021

04:30PM EDT Bright Minds Biosciences to Present at the 2021 LD Micro GlobeNewswire Inc

Jun 4, 2021

12:04AM EDT Benzinga Cannabis Capital Conference - June 4 Agenda Benzinga

May 17, 2021

06:50AM EDT Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that its shares will commence trading on the OTCQB Venture Market (the OTCQB) on May 17, 2021, under the symbol BMBIF. GlobeNewswire Inc

Share